A mortality analysis of letermovir prophylaxis for cytomegalovirus (CMV) in CMV-seropositive recipients of allogeneic hematopoietic cell transplantation

This post hoc mortality analysis of phase 3 data suggests that letermovir prophylaxis reduced all-cause mortality versus placebo in cytomegalovirus (CMV)-seropo

Saved in:

Bibliographic Details
Main Authors:	Ljungman, Per (Author) , Schmitt, Michael (Author) , Marty, Francisco M. (Author) , Maertens, Johan (Author) , Chemaly, Roy F. (Author) , Kartsonis, Nicholas A. (Author) , Butterton, Joan R. (Author) , Wan, Hong (Author) , Teal, Valerie L. (Author) , Sarratt, Kendra (Author) , Murata, Yoshihiko (Author) , Leavitt, Randi Y. (Author) , Badshah, Cyrus (Author)
Format:	Article (Journal)
Language:	English
Published:	2020
In:	Clinical infectious diseases Year: 2020, Volume: 70, Issue: 8, Pages: 1525-1533
ISSN:	1537-6591
DOI:	10.1093/cid/ciz490
Online Access:	Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1093/cid/ciz490 Verlag, lizenzpflichtig, Volltext: https://academic.oup.com/cid/article/70/8/1525/5513132
Author Notes:	Per Ljungman, Michael Schmitt, Francisco M. Marty, Johan Maertens, Roy F. Chemaly, Nicholas A. Kartsonis, Joan R. Butterton, Hong Wan, Valerie L. Teal, Kendra Sarratt, Yoshihiko Murata, Randi Y. Leavitt, and Cyrus Badshah

Description
Summary:	This post hoc mortality analysis of phase 3 data suggests that letermovir prophylaxis reduced all-cause mortality versus placebo in cytomegalovirus (CMV)-seropo
Item Description:	Published online June 8, 2019 Gesehen am 13.10.2020
Physical Description:	Online Resource
ISSN:	1537-6591
DOI:	10.1093/cid/ciz490